Intuitive Surgical’s Stock Hits 52-Week Low Despite Strong Q2, as Two Threats Converge
Published on 07/23/2026 at 18:13 | Redaktion boerse-global.de
Intuitive Surgical finds itself in an unusual bind. The robotic surgery leader delivered second-quarter results that beat analyst expectations on both revenue and earnings, yet its shares have tumbled to a new 52-week low of €298.05. The stock now trades at €299.35, down 38.8% since the start of 2026, and the selling pressure shows no sign of abating.
The disconnect between operational performance and market sentiment stems from two distinct but compounding headwinds: a cautious full-year forecast that disappointed investors hoping for an upgrade, and the sudden emergence of a formidable new competitor.
Q2 Beat Fails to Shift the Narrative
For the three months ended June 2026, Intuitive Surgical generated revenue of $2.89 billion, up 19% from a year earlier. Adjusted earnings per share came in at $2.80, well ahead of the consensus estimate of $2.48. The company also posted a 30-basis-point improvement in adjusted gross margin to 70%, while adjusted operating margin expanded by 330 basis points to 42%.
Global procedure volumes for the da Vinci and Ion systems grew roughly 16% year over year. Of the 468 da Vinci systems installed during the quarter, 246 were the new da Vinci 5 generation, up from just 180 units in the same period last year — a faster-than-expected adoption rate for the platform.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
Yet the market’s focus landed squarely on what management refused to do. The company maintained its full-year 2026 procedure growth guidance of 13.5% to 15.5%, declining to raise the range despite the strong second-quarter showing. Analysts had been hoping for an upgrade, and the decision to hold steady signaled caution about the second half.
The primary concern: the expiration of ACA health insurance subsidies in the United States. Intuitive’s management described the potential impact as “moderate,” but the guidance freeze suggests the company is bracing for a drag on elective, non-life-threatening procedures such as gallbladder and hernia repairs — precisely the types of surgeries that drive volume on its robotic platforms.
A Rival Finally Arrives
The timing could hardly be worse. On July 22, the FDA granted Johnson & Johnson marketing authorization for Ottava, its table-integrated soft-tissue surgical robot. The system is the first of its kind approved in the U.S. and reportedly reduces operating room footprint by 30% to 50%. Initial cleared indications include gastric bypass, gastrectomy, cholecystectomy, sleeve gastrectomy, appendectomy, and hiatal hernia repair.
Johnson & Johnson plans a phased commercial rollout, with expansion into Japan and Western Europe to follow. The entry directly challenges da Vinci and Medtronic’s Hugo system in a market where only about 8% of surgeries globally are currently robot-assisted — leaving plenty of room for competition.
A J.P. Morgan analyst noted that Johnson & Johnson will likely pursue additional approvals for urological procedures, a segment where Intuitive Surgical remains dominant with da Vinci.
Valuation Compression and Analyst Divergence
The stock now trades at 9.89 times expected annual revenue, its lowest multiple in 18 months and well below the 15.89 median. The 14-day relative strength index stands at 31.3, signaling oversold conditions. Over seven trading days, the shares lost nearly 15% of their value.
Analyst reactions have been mixed but largely cautious. Bernstein cut its price target from $750 to $685, while Stifel slashed its target from $670 to $550. Citigroup lowered its target to $500, and TD Cowen reduced its to $520. Goldman Sachs held firm at $558. Deutsche Bank stands out with a sell rating and a $366 target. Simply Wall St trimmed its fair-value estimate from $565.25 to $501.73, citing a lower revenue growth assumption of 12.14% versus the prior 13.09%.
Intuitive Surgical at a turning point? This analysis reveals what investors need to know now.
Institutional positioning tells a similar story of divergence. Dimensional Fund Advisors increased its stake by 3.6% in the first quarter to 645,181 shares, while CI Investments cut its position by 33.1%, selling 61,937 shares. Insider sales added to the negative signal: SVP Iman Jeddi sold 5,625 shares in early June at $420.55, and EVP Gary Loeb disposed of 400 shares in mid-June at $424.14.
Balance Sheet Provides a Floor
Despite the stock’s slide, Intuitive Surgical’s financial position remains robust. The company ended the quarter with $8.63 billion in cash and investments. Free cash flow for the first half reached $1.8 billion, up 71% from the prior-year period. That liquidity supports $379 million in share buybacks during the first half and continued investment in R&D for endoluminal and digital platforms.
Whether the U.S. procedure slowdown proves temporary or marks the beginning of a structural shift in the competitive landscape is the central question for investors. For now, the market is pricing in the worst-case scenario — even as the company’s own management describes the expected headwind as moderate.
Ad
Intuitive Surgical Stock: New Analysis - 23 July
Fresh Intuitive Surgical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
